Marvel Biosciences Corp. (TSXV: MRVL)
Health Care · Biotechnology · CA
CA$0.15
-11.76% today · -17.1% 1Y
Marvel Biosciences Corp. (TSXV: MRVL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $7.72M and employs 5 people.
Over the last twelve months the share price has lost 17.1%, trading between 0.12 and 0.40.
Tweenvest scores Marvel Biosciences Corp. across four factors: quality 7/100. Its strongest factor is quality.
MRVL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.72M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 0.59
- 52-week high
- CA$0.40
- 52-week low
- CA$0.12
- Avg volume (3M)
- —
- Shares outstanding
- 63.03M
- Employees
- 5
- Next earnings
- —
About Marvel Biosciences Corp.
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company’s lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer’s disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.
- Listed since
- Jul 13, 2021
- Exchange
- TSX Venture Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $263.51 | -0.55% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.76 | +0.10% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $145.40 | -0.49% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.05 | -0.18% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $835.68 | +0.20% |
| argenx SEENXTBR: ARGX | $65.85B | €877.20 | -2.75% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.41 | +0.23% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.